You are here

Article Text

Article menu
Download PDFPDF
Letter
Presence of rheumatoid factor and antibodies to citrullinated peptides in systemic lupus erythematosus
  1. I E A Hoffman1,
  2. I Peene1,
  3. L Cebecauer2,
  4. D Isenberg3,
  5. T W J Huizinga4,
  6. A Union5,
  7. L Meheus5,
  8. K De Bosschere5,
  9. F Hulstaert5,
  10. E M Veys1,
  11. F De Keyser1
  1. 1Department of Rheumatology, Ghent University Hospital, Ghent, Belgium
  2. 2Research Institute for Rheumatic Diseases, Piestany, Slovakia
  3. 3Centre For Rheumatology, University College London, London, UK
  4. 4Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands
  5. 5Innogenetics NV, Ghent, Belgium
  1. Correspondence to:
    Dr I Hoffman
    Department of Rheumatology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium; Ilse.Hoffmanugent.be

https://doi.org/10.1136/ard.2004.022111

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Rheumatoid factor (RF) is found commonly in patients with systemic lupus erythematosus (SLE), and has been associated with a more benign disease course.1,2 Anti-citrullinated peptide antibodies (ACPA) are more specific for rheumatoid arthritis (RA).3–5 Several assays for ACPA detection have been developed: among others, an enzyme linked immunosorbent assay (ELISA) for anti-cyclic citrullinated peptide (anti-CCP) antibodies3 and a line immunoassay (LIA) for antibodies to peptide A (pepA) and peptide B (pepB), two synthetic citrullinated peptides.4 Few reports exist about the presence of ACPA in SLE. Although patients with SLE are often part of the control group when determining the specificity of ACPA for RA, SLE alone is seldom studied. Mediwake et al found that 3/66 …

    View Full Text